Egle A - Search Results

1

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.

Greil R, Egle A, Villunger A. Greil R, et al. Among authors: egle a. Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.

2

Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.

Hufnagl C, Leisch M, Weiss L, Melchardt T, Moik M, Asslaber D, Roland G, Steininger P, Meissnitzer T, Neureiter D, Greil R, Egle A. Hufnagl C, et al. Among authors: egle a. Oncol Lett. 2020 Feb;19(2):1551-1558. doi: 10.3892/ol.2019.11192. Epub 2019 Dec 9. Oncol Lett. 2020. PMID: 31966080 Free PMC article.

3

C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients.

Schlick K, Magnes T, Huemer F, Ratzinger L, Weiss L, Pichler M, Melchardt T, Greil R, Egle A. Schlick K, et al. Among authors: egle a. J Clin Med. 2019 Oct 25;8(11):1791. doi: 10.3390/jcm8111791. J Clin Med. 2019. PMID: 31717722 Free PMC article.

4

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.

Wagner SM, Melchardt T, Egle A, Magnes T, Skrabs C, Staber P, Simonitsch-Klupp I, Panny M, Lehner B, Greil R, Keil F, Jäger U, Sillaber C. Wagner SM, et al. Among authors: egle a. Eur J Haematol. 2020 Mar;104(3):251-258. doi: 10.1111/ejh.13368. Epub 2020 Jan 10. Eur J Haematol. 2020. PMID: 31838747 Free PMC article.

5

Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.

Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R. Villunger A, et al. Among authors: egle a. Int J Cancer. 1996 Feb 8;65(4):498-505. doi: 10.1002/(SICI)1097-0215(19960208)65:4<498::AID-IJC18>3.0.CO;2-6. Int J Cancer. 1996. PMID: 8621234

6

2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

Gruber J, Geisen F, Sgonc R, Egle A, Villunger A, Boeck G, Konwalinka G, Greil R. Gruber J, et al. Among authors: egle a. Stem Cells. 1996 May;14(3):351-62. doi: 10.1002/stem.140351. Stem Cells. 1996. PMID: 8724701

7

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, Greil R. Egle A, et al. Eur J Immunol. 1996 Dec;26(12):3119-26. doi: 10.1002/eji.1830261244. Eur J Immunol. 1996. PMID: 8977313

8

The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.

Geley S, Hartmann BL, Kapelari K, Egle A, Villunger A, Heidacher D, Greil R, Auer B, Kofler R. Geley S, et al. Among authors: egle a. FEBS Lett. 1997 Jan 27;402(1):36-40. doi: 10.1016/s0014-5793(96)01496-2. FEBS Lett. 1997. PMID: 9013854

9

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.

Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R. Egle A, et al. Br J Haematol. 1997 May;97(2):418-28. doi: 10.1046/j.1365-2141.1997.382680.x. Br J Haematol. 1997. PMID: 9163609

10

Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.

Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R, Greil R. Villunger A, et al. Among authors: egle a. Blood. 1997 Jul 1;90(1):12-20. Blood. 1997. PMID: 9207432

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results